Fresenius acquired Merck’s biosimilars business

0

The operation follows the Merck’s decision to focus its future strategy on its pipeline of innovative medicines. The deal includes an upfront payment of 170 million €, milestone payments of up to 500 million € plus royalties on future product sales. Merck and Fresenius will also enter into supply and services agreements for drug development support and manufacturing services. Closing is expected in the second half of 2017, subject to regulatory approvals. Merck’s Biosimilars business is located in Aubonne and Vevey in Canton de Vaud, Switzerland and it is focused on oncology and inflammatory disorders.

SHARE

LEAVE A REPLY

Please enter your comment!
Please enter your name here